



Colorectal Cancer: Recent Advances and Challenges

Guest Editor:

Dr. Eva Martínez-Balibrea

Catalan Institute of Oncology,
Germans Trias i Pujol research
institute (IGTP), Carretera de Can
Ruti, camí de les escoles s/n,
08916 Badalona (Barcelona),
Spain

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Colorectal cancer (CRC) was the third most common cancer worldwide in 2018, accounting for more than 800,000 deaths. Despite the successful recent introduction of immunotherapies or PARP inhibitors in other cancers, CRC patients are still being treated in the same way as they were 20 years ago: with combinations of cytotoxic chemotherapy and anti-targeted drugs. Immunotherapies are suitable for less than 5% of metastatic patients harboring microsatellite-unstable or hypermutated tumors. Moreover, specific biomarkers, apart from RAS mutations whose detection is used to avoid the use of anti-EGFR drugs, are lacking.

This Special Issue will present a selection of original works and reviews describing recent advances and current challenges in the field of CRC treatment, including the discovery of new drug targets, response and resistance biomarkers, descriptions of specific subgroups of patients who respond to specific treatments (i.e., immunotherapies), and the development of new generation drugs (PROTACS, nanotechnology-based therapies, etc.).





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI